TherapeuticsMD (NASDAQ: TXMD) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare TherapeuticsMD to related companies based on the strength of its dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Valuation & Earnings
This table compares TherapeuticsMD and its competitors top-line revenue, earnings per share (EPS) and valuation.
TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
73.8% of TherapeuticsMD shares are held by institutional investors. Comparatively, 65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 23.9% of TherapeuticsMD shares are held by insiders. Comparatively, 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent recommendations for TherapeuticsMD and its competitors, as provided by MarketBeat.
||Strong Buy Ratings
TherapeuticsMD currently has a consensus target price of $15.00, indicating a potential upside of 148.34%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 21.42%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, equities analysts plainly believe TherapeuticsMD is more favorable than its competitors.
This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
TherapeuticsMD has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.
TherapeuticsMD beats its competitors on 7 of the 12 factors compared.
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.